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Abstract: Fracture haematoma forms immediately after fracture and is considered essential for the
bone healing process. Its molecular composition has been briefly investigated with our current
understanding being based on animal studies. This study aims to analyse the inflammatory
cytokine content of fracture haematoma in humans and determine its effect on osteoprogenitor
cells. Twenty-three patients were recruited following informed consent. Peripheral blood, fracture
haematoma and bone were collected. A Luminex assay on the levels of 34 cytokines was performed
and autologous peripheral blood samples served as control. Mesenchymal Stem Cells (MSCs) were
isolated following collagenase digestion and functional assays were performed. Gene expression
analysis of 84 key osteogenic molecules was performed. Thirty-three inflammatory cytokines were
found to be significantly raised in fracture haematoma when compared to peripheral serum (p < 0.05).
Amongst the most raised molecules were IL-8, IL-11 and MMP1, -2 and -3. Fracture haematoma did
not significantly affect MSC proliferation, but ALP activity and calcium deposition were significantly
increased in the MSCs undergoing osteogenic differentiation. Medium supplementations with
fracture haematoma resulted in a statistically significant upregulation of osteogenic genes including
the EGF, FGF2 and VEGFA. This seems to be the pathway involved in the osteogenic effect of
fracture haematoma on bone cells. In conclusion, fracture haematoma is found to be a medium rich
in inflammatory and immunomodulatory mediators. At the same time, it contains high levels of
anti-inflammatory molecules, regulates osteoclastogenesis, induces angiogenesis and the production
of the extracellular matrix. It appears that fracture haematoma does not affect osteoprogenitor cells
proliferation as previously thought, but induces an osteogenic phenotype.
Keywords: fracture haematoma; cytokines; bone healing; mesenchymal stem cells
1. Introduction
Bone healing is a complex process of interlinked events that leads to fracture healing [1–3].
It starts with the formation of haematoma, which is a rich medium characterized by abundance
of a great variety of cells types, cytokines and chemokines [1]. It has been suggested that fracture
haematoma is the foundation of bone healing and an essential element for the overall healing process [4].
This argument is supported clinically but also experimentally by several studies, suggesting that it
contains all the required signals to initiate and actively promote the formation of new bone [4–8].
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Implantation of fracture haematoma into soft tissues was also associated with commencement of
a healing response characterized by the deposition of calcium [5]. On the contrary, some authors
have shown detrimental results when fracture haematoma was removed [4,6,7]. In clinical studies,
the debridement and irrigation of the fracture site within two days after fracture has shown to have the
worst prognosis in terms of healing as compared to a debridement at a later stage [6]. Moreover, murine
open osteotomies healed more slowly than closed fractures, an outcome attributed to the irrigation of
fracture haematoma [7].
Fracture haematoma seems to be important in bone healing, but its exact cellular and molecular
composition remains obscure. The limited evidence currently available mostly involves animal models.
However, their fracture healing physiology is different to that of humans and therefore is not directly
comparable. The aims of this study were two-fold. Firstly, it aims to analyse the inflammatory cytokine
content of human fracture haematoma; secondly to determine the proliferative and osteogenic capacity
of fracture haematoma compared to peripheral blood and standard culture media.
2. Materials and Methods
2.1. Patients
Between January 2015 and August 2016, patients were invited to participate in this study.
Ethics committee approval was obtained (Ref number Q1206/127). Inclusion criteria included healthy
adult patients admitted in our institution with closed, simple (two-part) long bone fractures requiring
operative treatment. The exclusion criteria included pathological fractures, local and systemic
inflammatory conditions and use of steroids or previous radiotherapy. Patients to whom surgery was
delayed for more than 48 h from injury were also excluded.
In total, 23 consecutive patients (15 males; mean age of 41.3 years; range: 23 to 60 years) met the
inclusion and participated in this study. The average time to surgery was 23 h (9 to 42 h). The most
prevalent injury was a tibial shaft fracture (n = 16) followed by fibular (n = 3), femoral (n = 2) and
radial fractures (n = 2).
2.2. Isolation and Preparation of Peripheral Serum and Fracture Haematoma
A total of 10 mL of peripheral venous blood was collected at the induction of surgery. Prior to
any surgical intervention, 0.5 mL of fracture haematoma was also collected. Fracture haematoma
collection was performed percutaneously, before any surgical intervention. Prior to the aspiration of
fracture haematoma the needle position was checked on anteroposterior and lateral fluoroscopic views.
The blood was collected into serum separation containers without anticoagulant and allowed to clot.
It was processed within 2 h of collection and was kept on ice. The clotted blood was then centrifuged
at 1500× g rpm for 20 min and the serum was extracted. All serum was aliquoted in Eppendorf tubes
and was stored in a −80 ◦C freezer before use.
2.3. Isolation of Mesenchymal Stem Cells (MSCs)
In addition to the blood collection, bone was also harvested intra-operatively from the fracture
site from 12 patients (previously described protocols) [9–14]. MSCs were isolated from bone using
enzymatic digestion with collagenase 0.25% (Stem Cell Technologies, Vancouver, BC, Canada) for
4 h (37 ◦C, 5% CO). 20 × 106 collagenase-released cells were placed into 25 cm2 flasks and grown
to passage (p) 3. Phenotypic characterization was performed for all donors to depict the nature of
cultures grown using flow cytometry (standard panel of cell surface receptors CD73, CD90 and CD105,
and of haematopoetic markers CD45, CD34, CD11b, CD79α and HLA-DR) [9–14]. All cell samples
were positive for the three markers, and tested negative for the negative marker cocktail containing all
of the relevant haematopoetic markers (Figure 1).
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Figure 1. The phenotype of Mesenchymal Stem Cells used in the study. (n = 12).
2.4. Analysis of Proliferation
The effect of fracture haematoma on MSCs’ proliferation was assessed on cells of 12 donors
according to the number of viable cells (XTT assay). Controls included cells grown on peripheral
serum and standard media containing fetal calf sera. For the XTT assay 96-well-plates were used and
the cells were seeded in triplicate. The cells were allowed to proliferate for 72 h and on day 3, XTT dye
was added according to manufacturers’ instructions. The optical densities were proportional to the
number of viable cells.
2.5. Analysis of Osteogeni Differentiation
Osteogenic induction was performed using p3 cells from MSCs from 10 donors using standard
protocols previously described [9–14]. Briefly, the quantitative measurement of Alkaline Phosphatase
(ALP) activity (Sigma, St. Louis, MO, USA, N-7653) in the cellular protein fraction was performed
at day 10 following osteogenic induction. The total calcium deposition was measured at day 21 of
osteogenic differentiation (Calcium Colorimetric Assay Kit, Sigma-Aldrich. MAK022, St. Louis, MO,
USA). Both assays were performed under manufacturer instructions.
2.6. Osteogenic RT2 Profiler PCR Array
Cells from five patients were cultured under osteogenic conditions with either autologous
peripheral serum or fracture haematoma. On day 10 of osteogenic differentiation, the cells
were harve ted and their expression of ost oge ic m lecul s was assessed with a rtPCR array.
These experiments were performed in QIAGEN laboratories and the genes examined can be found in
Table 1.
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Table 1. List of genes examined by the osteogenic RT2 Profiler PCR Array.
Symbol Description
ACVR1 Activin A receptor, type I
AHSG Alpha-2-HS-glycoprotein
ALPL Alkaline phosphatase, liver/bone/kidney
ANXA5 Annexin A5
BGLAP Bone gamma-carboxyglutamate (gla) protein (Osteocalcin)
BGN Biglycan
BMP1 Bone morphogenetic protein 1
BMP2 Bone morphogenetic protein 2
BMP3 Bone morphogenetic protein 3
BMP4 Bone morphogenetic protein 4
BMP5 Bone morphogenetic protein 5
BMP6 Bone morphogenetic protein 6
BMP7 Bone morphogenetic protein 7
BMPR1A Bone morphogenetic protein receptor, type IA
BMPR1B Bone morphogenetic protein receptor, type IB
BMPR2 Bone morphogenetic protein receptor, type II (serine/threonine kinase)
CALCR Calcitonin receptor
CD36 CD36 molecule (thrombospondin receptor)
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast)
CHRD Chordin
COL10A1 Collagen, type X, alpha 1
COL14A1 Collagen, type XIV, alpha 1
COL15A1 Collagen, type XV, alpha 1
COL1A1 Collagen, type I, alpha 1
COL1A2 Collagen, type I, alpha 2
COL2A1 Collagen, type II, alpha 1
COL3A1 Collagen, type III, alpha 1
COL5A1 Collagen, type V, alpha 1
COMP Cartilage oligomeric matrix protein
CSF1 Colony stimulating factor 1 (macrophage)
CSF2 Colony stimulating factor 2 (granulocyte-macrophage)
CSF3 Colony stimulating factor 3 (granulocyte)
CTSK Cathepsin K
DLX5 Distal-less homeobox 5
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
FGF1 Fibroblast growth factor 1 (acidic)
FGF2 Fibroblast growth factor 2 (basic)
FGFR1 Fibroblast growth factor receptor 1
FGFR2 Fibroblast growth factor receptor 2
FLT1 Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
FN1 Fibronectin 1
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Table 1. Cont.
Symbol Description
GDF10 Growth differentiation factor 10
GLI1 GLI family zinc finger 1
ICAM1 Intercellular adhesion molecule 1
IGF1 Insulin-like growth factor 1 (somatomedin C)
IGF1R Insulin-like growth factor 1 receptor
IGF2 Insulin-like growth factor 2 (somatomedin A)
IHH Indian hedgehog
ITGA1 Integrin, alpha 1
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit)
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
MMP10 Matrix metallopeptidase 10 (stromelysin 2)
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
MMP8 Matrix metallopeptidase 8 (neutrophil collagenase)
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
NOG Noggin
PDGFA Platelet-derived growth factor alpha polypeptide
PHEX Phosphate regulating endopeptidase homolog, X-linked
RUNX2 Runt-related transcription factor 2
SERPINH1 Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)
SMAD1 SMAD family member 1
SMAD2 SMAD family member 2
SMAD3 SMAD family member 3
SMAD4 SMAD family member 4
SMAD5 SMAD family member 5
SOX9 SRY (sex determining region Y)-box 9
SP7 Sp7 transcription factor
SPP1 Secreted phosphoprotein 1
TGFB1 Transforming growth factor, beta 1
TGFB2 Transforming growth factor, beta 2
TGFB3 Transforming growth factor, beta 3
TGFBR1 Transforming growth factor, beta receptor 1
TGFBR2 Transforming growth factor, beta receptor II (70/80kDa)
TNF Tumor necrosis factor
TNFSF11 Tumor necrosis factor (ligand) superfamily, member 11
TWIST1 Twist homolog 1 (Drosophila)
VCAM1 Vascular cell adhesion molecule 1
VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor
VEGFA Vascular endothelial growth factor A
VEGFB Vascular endothelial growth factor B
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Table 1. Cont.
Symbol Description
ACTB Actin, beta
B2M Beta-2-microglobulin
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HPRT1 Hypoxanthine phosphoribosyltransferase 1
RPLP0 Ribosomal protein, large, P0
2.7. Statistical Analysis
Assumption of normality was tested with a one-sample Kolmogorov–Smirnov test. Data are
expressed as mean (standard deviation) or median (range) as appropriate. Parametric and
nonparametric data were compared using the paired Student’s t-test and non-parametric tests
respectively. The cut-off value for significance was p = 0.05. All calculations were done using the
Statistical Package for the Social Sciences (SPSS, version 25.0, IBM, New York, NY, USA).
3. Results
3.1. Cytokines in Fracture Haematoma
Of the 37 cytokines measured in fracture haematoma and peripheral serum, IL-27 (p28 subunit),
IL-32 and IL-34 were out of the detection range for the assay [Table 2]. All the rest, apart from
osteocalcin, had a statistically significantly higher concentration in fracture haematoma than the
respective autologous peripheral serum. The lowest statistically significant measured value was seen
in IFN-y and IL-28a, both at 1.69-fold increase. The highest measured significant value was seen
in IL-11, at 1698.03-fold to the peripheral serum. Other particularly high differences included the
IL-8 at 235.31-fold increase, MMP2 at 13.39-fold increase, MMP1 at 13.34-fold increase and MMP3 at
12.97-fold increase.
Interestingly, the levels of anti-inflammatory molecules were raised alongside the inflammatory
cytokines. IL-10, was significantly higher in fracture haematoma at a value of 5-fold (p < 0.001).
IL-11, a potent anti-inflammatory molecule produced by cells of mesenchyme origin, was statistically
significant increased compared to peripheral circulation levels (1698.03-fold difference). IL-12 and IFN
that have cytoprotective and antiresorptive effect were also raised [1].
As well as performing concentration analysis, several linear regression analyses were performed
to ascertain a relationship between other measured variables. Age, gender, time between fracture and
sample collection, white cell counts (WCC), neutrophil counts and platelet counts were compared
with cytokine concentrations in fracture haematoma and peripheral serum. Of all the variables, time
between fracture and sample collection, WCC, neutrophil counts and platelet counts showed trends
with cytokine concentrations. Total WCC, neutrophil counts and platelet counts were seen to correlate
with several cytokines. Total WCC were seen to significantly correlate positively with BAFF (r2 = 0.39),
INF-y (r2 = 0.34), IL-2 (r2 = 0.31), IL-19 (r2 = 0.29), IL-26 (r2 = 0.42), IL-28a (r2 = 0.30), IL-29 (r2 = 0.40),
sTNF-R1 (r2 = 0.34), sTNF-R2 (r2 = 0.32), TSLP (r2 = 0.40) and TWEAK (r2 = 0.59). Similarly, significantly
positive correlations were seen between neutrophil counts and fracture haematoma concentrations
of BAFF (r2 = 0.29), IL-26 (r2 = 0.31) and IL-29 (r2 = 0.35). Platelet counts were seen to significantly
correlate positively with alternative cytokines in fracture haematoma, namely sCD30 (r2 = 0.40), IL-20
(r2 = 0.44), IL-26 (r2 = 0.42), MMP-3 (r2 = 0.31) and osteopontin (r2 = 0.34).
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Table 2. The cytokine concentrations measures in the study. Mean values in fracture haematoma and
peripheral circulation.
Cytokine Fracture Haematoma Peripheral Serum
APRIL 357 (263–452.3) ng/mL 106.4 (67.35–136.7) ng/mL
BAFF 64.48 (40.63–72.24) ng/mL 14.25 (10.76–16.22) ng/mL
sCD30 957.3 (681.3–1442) pg/mL 683.3 (471.6–1036) pg/mL
Chitinase-3-like 1 70.36 (49.71–94.21) ng/mL 23.51 (21.07–32.24) ng/mL
GP130 281.3 (224.9–376.2) ng/mL 112.8 (99.24–155.5) ng/mL
IFNa2 81.16 (60.3–102.9) pg/mL 41.52 (35.23–47.15) pg/mL
IFNb 1017 (666.3–1586) pg/mL 179.9 (111.8–284.8) pg/mL
IFNy 42.42 (30.81–51.98) pg/mL 29.91 (24.74–34.85) pg/mL
IL-2 20.21 (14.91–24.75) pg/mL 10.16 (8.85–11.31) pg/mL
sIL-6Ra 75.51 (52.19–96.2) ng/mL 25.18 (19.85–28.59) ng/mL
IL-8 5.243 (1.579–12.23) ng/mL 0.032 (0.027–0.045) ng/mL
IL-10 42.78 (17.84–60.33) pg/mL 9.81 (7.53–11.13) pg/mL
IL-11 797 (197.8–2376) pg/mL 1.75 (1.01–5.16) pg/mL
IL-12 (p40) 104.5 (63.3–137) pg/mL 29.33 (24.09–41.73) pg/mL
IL-12 (p70) 3.12(2.07–4.19) pg/mL 1.47 (1.21–1.75) pg/mL
IL-19 32.81 (29.53–43.87) pg/mL 19.08 (17.04–23.69) pg/mL
IL-20 176.4 (116.6–217.6) pg/mL 81.39 (70.05–98.79) pg/mL
IL-22 67.41 (42.41–84.45) pg/mL 19.76 (14.48–28) pg/mL
IL-26 38.09 (21.98–47.16) pg/mL 10.43 (8.138–13.82) pg/mL
IL-27 (p28) 38.97 (24.28–47.83) pg/mL 10.43 (7.93–13.82) pg/mL
IL-28a 104.3 (86.71–123.3) pg/mL 64.35 (56.21–71.7) pg/mL
IL-29 98.41 (54.82–119.6) pg/mL 44.21 (35.62–50.5) pg/mL
IL-35 454.9 (355.9–564.6) pg/mL 219.1 (188.2–235.7) pg/mL
LIGHT 138.6 (69–267.2) pg/mL 20.87 (14.38–30.83) pg/mL
MMP-1 10.37 (6.12–16.65) ng/mL 0.94 (0.24–1.83) ng/mL
MMP-2 83.01 (36.41–107.3) ng/mL 6.10 (3.98–9.03) ng/mL
MMP-3 77.6 (38.49–122.7) ng/mL 7.54 (4.20–11.24) ng/mL
Osteocalcin 3.93 (1.67–7.10) ng/mL 2.90 (1.71–4.78) ng/mL
Osteopontin 179.4 (105.9–335.6) ng/mL 74.4 (56.48–98.75) ng/mL
Pentraxin 3 7.27 (3.59–9.50) ng/mL 0.86 (0.52–1.40) ng/mL
sTNF-R1 25.09 (15.73–31.81) ng/mL 8.58 (6.67–10.21) ng/mL
sTNF-R2 97.69 (76.1–124.3) ng/mL 16.82 (10.84–22.27) ng/mL
TSLP 105.9 (69.84–133.8) pg/mL 38.42 (33.79–46.08) pg/mL
TWEAK 1.80 (0.94–2.43) pg/mL 0.82 (0.56–0.95) pg/mL
sCD163 585.8 (471.6–1181) ng/mL 181.7 (124.3–293.6) ng/mL
3.2. Proliferative Potential of Fracture Haematoma
An XTT assay was performed on MSCs to determine the proliferative potential of fracture
haematoma compared to FBS and autologous serum (Figure 2). No statistically significant differences
in proliferation rates were seen between the three different culture conditions.
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Figure 2. Box plots sh wing the ratio, expr ssed as a percentage, of optical densities measured from the XTT
proliferation assay b tween FBS, autologous serum and fracture haematoma. FBS = Foetal Bovine Serum.
3.3. Osteogenic Potential of Fracture Haematoma
3.3.1. ALP Activity Assay
The measured ALP activity in osteoblasts cultured in 10% fracture haematoma was significantly
higher (74%; p < 0.001) when compared to those cells supplemented with 10% autologous serum
(Figure 3). Similarly, the ALP activity of cells complemented with fracture haematoma was 119%
higher (p < 0.0001) compared to that of 10% FBS supplementation.
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3.3.2. Calcium Assay
A 70% increase in calcium deposition was seen in cells cultured in fracture haematoma compared
to autologous peripheral serum (Figure 4). The difference in cells cultured in human peripheral serum
versus fetal animal sera was 112%.
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3.3.3. Gene Expression Analysis
A number of molecules demonstrated significant upregulation when exposed to fracture
haematoma [Table 3]. Among the over- xpressed molecul s, EGF expr ssion was upregulated
by 35-fold (p < 0.01). VCAM1 and VEGFA we upregulated by 20.5- and 5.2-fold respectiv ly (p < 0.01).
Other molecules that were found upregulated included chordin (5.9-fold), SOX9 (3.8-fold), FGF2
(3.7-fold) and BMP4 (2.6-fold) (all p < 0.05). Statistically significant down-regulation of several molecules
was also noted. BMP3 and PHEX showed the highest down-regulation ith 8.0-fold and 7.2-fold
respectively. BMPR1B, COL3A1 and COL14A1 were also statistically significant do n-regulated.
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Table 3. Gene expression of autologous cells supplemented with fracture haematoma and
peripheral serum.
Gene Fold Difference in Expression
Upregulated
Epidermal Growth Factor 35.1
Vascular cell adhesion protein 1 (EGF) 20.5
GLI family zinc finger 1 (GLI) 13.0
Fms-related tyrosine kinase 1 (vascular endothelial growth
factor/vascular permeability factor receptor) (FLT1) 10.8
Chordin (CHRD) 5.9
Vascular Endothelial Growth Factor-A (VEGFA) 5.2
SRY (sex determining region Y)-box 9 (SOX9) 3.8
Fibroblast growth factor 2 (FGFR2) 3.7
Bone morphogenetic protein 4 (BMP4) 2.6
Downregulated
Bone morphogenetic protein 3 (BMP3) −8.0
Phosphate regulating endopeptidase homolog, X-linked (PHEX) −7.2
Bone morphogenetic protein receptor, type IB (BMPR1B) −4.0
Tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11) −3.9
Collagen, type III, alpha 1 (COL3A1) −3.2
Sp7 transcription factor (SP7) −2.8
Collagen, type XIV, alpha 1 (COL14A1) −2.6
4. Discussion
Our understanding on the role of fracture haematoma in humans is largely obscure and based
on animal studies. This study attempts to expand our current understanding on the composition of
fracture haematoma and present its direct effect on the cellular functions and expression in vitro.
Previous research has only dealt with only certain cytokines including IL-6, IL-8 IL-10, IL-12,
MCP and M-CSF [15–18]. Our study is in agreement with some animal studies showing significant
increases in the IL-8 and IL-10 cytokines when compared to peripheral blood [15–17]. Differences with
previous research were also noted. Significantly higher concentrations of IL-10 and IL-12 are published
in the literature; in the case of IL-12 (p70), levels of 591 ± 326 pg/mL were reported compared to a
median value of 3.12 pg/mL (2.11–3.73 IQR) measured by in our study. These differences could be
attributed to the method of fracture haematoma isolation, as Hauser et al. utilised urokinase to release
cytokines from the fibrin matrix [16]. Hauser et al. were also unable to detect levels of IL-2 in their
study. This could be potentially due to the sample preparation.
The baseline levels of these cytokines in peripheral circulation in healthy controls are largely
unknown. From the limited evidence available IL-8 levels ranged between 3.00 and 3.5 pg/mL in the
general population while the mean value in patients with fracture was 32 pg/mL in our study [19].
IL-11 healthy control levels were found to average at 24.6 pg/mL [20]. In our study, peripheral
levels were only 1.75 pg/mL in peripheral circulation and 797 pg/mL locally in fracture haematoma.
Similarly, IL-10 levels were 113.2 pg/mL in healthy controls while 9.81 pg/mL in our study [21].
As already reported by other studies, the levels of anti-inflammatory molecules like IL-10 and
IL-11 reduce in some inflammatory conditions like infection and psoriasis [22–24]. However, further
elucidation of their exact role in humans is needed.
In addition to previous published evidence, the herein study adds significant evidence on the
haematoma composition and the biology of the initial fracture healing response. The presence of
increased levels of several inflammatory and immunomodulatory molecules is noted. In addition to
IL-6 and IL-12, other inflammatory molecules are present in haematoma including sTNF-R1, Interferons,
sCD30, BAFF Chitinase-3-like 1 sTNF-R2, IL-22, IL-26, Pentaxin-3 [25]. Their presence suggests that
inflammation is the landmark of the early stages of bone healing. At the same time, it also becomes
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evident that strong anti-inflammatory signals are present in the fracture haematoma. The levels
of IL-10 (4-fold), IL-19 (2-fold), IL-27 (3-fold increase), IL-28a (2-fold increase) and IL-11 (450-fold
increase); all these molecules are considered major anti-inflammatory cytokines [19,20]. Similarly to
the inflammation, molecules known to promote osteoclastogenesis like TWEAK were present but
at the same time IL-29 and IL-35 that are known to inhibit osteoclastogenesis were also present
in increased concentrations [26–29]. Several MMPs and the TSLP known to promote collagen and
extracellular matrix synthesis were also present [30–32]. Evidence that angiogenesis is initiated early
is also obvious by the increased levels of CD163 [33,34]. Finally, IL-8, a chemo-attractant of bone
progenitor cells were also present in increased concentrations [35]. The presence of the above molecules
in increased concentrations highlight the complexity of the interactions of molecules of the early stages
of fracture healing.
Our study also investigated the relationship between the levels of these cytokines to fracture
characteristics and circulating numbers of specific cell types. Only one cytokine measured, TWEAK,
exhibited a significant trend against time from fracture. One potential explanation for this decrease could
be the reduction in inflammatory cell counts observed in fracture haematoma as time progresses [18,36].
In a similar manner, the significant trends observed between certain cytokines, patient peripheral
WCC and neutrophil counts could be attributed to the pro-inflammatory state encountered following
trauma. Platelet counts were also found to significantly correlate with sCD30, IL-20, IL-26, MMP-3 and
osteopontin. Although the underlying mechanism is currently obscure, the chemotactic actions of
PDGF produced by the cells could be responsible for these results.
In the second part of the study, we tried to identify what is the effect of fracture haematoma on
osteoprogenitor cells in vitro. Surprisingly, fracture haematoma did not affect MSC proliferation but
a positive effect of osteogenic differentiation was noted. In line with previous animal studies this
effect can be attributed to the upregulated cytokine levels [37]. In particular, evidence suggests that
IL-6 negatively regulates the proliferation of osteoblasts in vitro [38]. IL-22 was found to promote
osteogenesis but had no effect on MSCs proliferation [39]. High levels of IL-10 were found to induce
an osteogenic phenotype [40]. IFN-γ can induce the apoptosis of MSCs while IL-27 can modulate their
proliferation [41]. Further elucidation of the influence of the local microenvironment on the actions
of these cytokines is needed; these molecules could potentially have dual or even opposing roles in
different conditions.
In an attempt to further explain the finding of the functional assays, gene expression analysis was
performed. MSCs were cultured with osteogenic medium containing either autologous peripheral
serum or fracture haematoma. The cell cultures with fracture haematoma showed higher expression
of a number of genes implicated in osteogenesis. More specifically, a strong statistically significant
expression of the EGF was noted. EGF is known to promote osteogenesis and bone healing by several
studies [42]. VEGFA and FGF2 were found upregulated in the herein study. Both molecules are known
to regulate and promote osteogenic differentiation [43]. SOX9, a transcription factor implicated in MSC
differentiation, was also upregulated in cell exposed to fracture haematoma [44]. The significance
of the down-regulated molecules is difficult to explain. BMP3 showed the highest downregulation.
BMP3 suppresses osteogenic differentiation and inhibits bone formation, so its down-regulation is an
indicator of enhanced osteogenesis [45]. The significance of the remaining down-regulated genes is
currently unknown. It should be pointed out that BMPs, TGF beta, and Runx2 were expressed at the
same level as many other cytokines. The herein study does not support any preferential role for these
three classes of molecules in the healing process.
Overall, this study provides evidence on the osteogenic effect of fracture haematoma, which seems
to be related to the upregulation of expression of several molecules. The study also provides evidence
on the inflammatory profile of fracture haematoma in humans, describing the molecules present in
fracture haematoma and their concentration. Expanding our understanding on human biology is
crucial as the majority of our understanding in regards to bone healing in humans derive from animal
models. Critical differences in the presences and levels of these cytokines exist between the different
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animal models and humans [1,15]. For example, in the study of Horst et al., IL-8 levels were 658.29 ±
84.11 pg/mL at 14 h following fracture in pigs while in the peripheral serum concentration was 148.90
± 25.85 pg/mL. The mean value in humans was 5.243 (1.579–12.23) ng/mL, which is approximately
8-times higher. Significant differences in other fracture haematoma cytokines between animals and
humans exists (reviewed and presented by Walters et al.) [1]. In addition to the levels of the cytokines,
animals exhibit differences in the composition of bone, the phenotype of bone cells, several bone cell
responses including their response to trauma and inflammation [46–54]. The mechanical forces exerted
on the bone and anatomy of the bones in animals are significantly different to that of humans [46–54].
These differences could explain the enhanced recovery following fracture seen in small species in
comparison to bigger animal models but also to humans.
Several future directions can be considered based on the results of this study. Firstly, there is
need to elucidate the role and function of these inflammatory cytokines found in fracture haematoma.
There is scope to further expand on the reactive oxygen species that are produced under inflammatory
or ischemic conditions due to blood supply disruption vessel soft tissue damage. The mechanisms
governing the oxidative stress and relation to the presence and levels of these cytokines might allow us
to uncover the exact mechanism of cell damage during the fracture healing process. Correlation of
the mechanical environment and the levels of these growth factors is a novel are of further research.
For instance, it is known that the mechanical environment affects size and shape of callus, hence, it is
likely that a different levels of growth factors are seen between stable fractures and those allowed to
heal with relative stability [47,49]. Another area of interest is the inhomogeneity of fracture heamatoma,
especially at the early stages, when the cells are mainly localized near the ruptured periosteum at
the periphery [47,49]. Hence, exploring the role of the cells present in fracture haematoma and their
contribution in the local phenotype is needed. There is vivid interest to investigate whether any of
these molecules can serve as biomarker for delayed unions or non-union. Maybe the modulations
of the levels of these inflammatory cytokines can provide novel strategies to enhance bone healing.
In a similar manner, further studies are sought to investigate the relation of these molecules to the
expression of osteogenic genes. Unfortunately, due to limited sample size this was not feasible in
our study. Recent research has shown some promise, with TNF-α improving fracture healing in a
murine model, but this area of biological response modification is still evolving [55]. The wide range
of molecules covered in the herein study opens avenues for new molecular targets. With the advent
of molecular therapy in fracture healing, this research could provide the basis for future treatments,
ultimately reducing fracture healing times and the burden of fracture non-union.
5. Conclusions
Fracture haematoma is a rich medium in which inflammatory molecules are present, being
significantly elevated compared to the levels usually met in the peripheral circulation. In addition
to several inflammatory and immunomodulatory molecules, fracture haematoma seems to contain
high levels of anti-inflammatory molecules, regulate osteoclastogenesis and induce angiogenesis and
the production of the extracellular matrix. In-vitro functional assays highlighted that fracture
haematoma does not affect the proliferation of MSCs, however, it exerts an osteogenic effect.
This osteogenic induction is explained by the overexpression of several osteogenic molecules including
EGF, FGFR2 and VEGFA.
Author Contributions: I.P. and G.W. were responsible for performing experiments, analysed the data and prepared
the first draft paper. M.P. has assisted in the gene analysis and the final editing of the manuscript. T.A.E. provided
expertise and was involved in final editing of the manuscript. I.P. and P.V.G. overlooked the project, performed
the final edits and the revisions of the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This study was supported by AO-UK.
Conflicts of Interest: The authors report no conflicts of interest. The authors alone are responsible for the content
and writing of the paper. No benefits in any form have been received or will be received from a commercial party
related directly or indirectly to the subject of this article.
J. Clin. Med. 2020, 9, 47 13 of 15
References
1. Walters, G.; Pountos, I.; Giannoudis, P.V. The cytokines and micro-environment of fracture haematoma:
Current evidence. J. Tissue Eng. Regen. Med. 2018, 12, e1662–e1677. [CrossRef] [PubMed]
2. Pountos, I.; Georgouli, T.; Pneumaticos, S.; Giannoudis, P.V. Fracture non-union: Can biomarkers predict
outcome? Injury 2013, 44, 1725–1732. [CrossRef] [PubMed]
3. Pountos, I.; Giannoudis, P.V. Biology of mesenchymal stem cells. Injury 2005, 36 (Suppl. 3), S8–S12. [CrossRef]
[PubMed]
4. Grundnes, O.; Reikerås, O. The importance of the hematoma for fracture healing in rats. Acta Orthop. Scand.
1993, 64, 340–342. [CrossRef] [PubMed]
5. Schmidt-Bleek, K.; Schell, H.; Kolar, P.; Pfaff, M.; Perka, C.; Buttgereit, F.; Duda, G.; Lienau, J.
Cellular composition of the initial fracture hematoma compared to a muscle hematoma: A study in
sheep. J. Orthop. Res. 2009, 27, 1147–1151. [CrossRef] [PubMed]
6. Park, S.H.; Silva, M.; Bahk, W.J.; McKellop, H.; Lieberman, J.R. Effect of repeated irrigation and debridement
on fracture healing in an animal model. J. Orthop. Res. 2002, 20, 1197–1204. [CrossRef]
7. Park, S.H.; O’Connor, K.; Sung, R.; McKellop, H.; Sarmiento, A. Comparison of healing process in open
osteotomy model and closed fracture model. J. Orthop. Trauma 1999, 13, 114–120. [CrossRef]
8. Grundnes, O.; Reikerås, O. The role of hematoma and periosteal sealing for fracture healing in rats.
Acta Orthop. Scand. 1993, 64, 47–49. [CrossRef]
9. Pountos, I.; Georgouli, T.; Henshaw, K.; Howard, B.; Giannoudis, P.V. Mesenchymal Stem Cell physiology
can be affected by antibiotics: An in vitro study. Cell. Mol. Biol. 2014, 60, 1–7.
10. Pountos, I.; Georgouli, T.; Henshaw, K.; Bird, H.; Giannoudis, P.V. Release of growth factors and the effect of
age, sex, and severity of injury after long bone fracture. A preliminary report. Acta Orthop. 2013, 84, 65–70.
[CrossRef]
11. Pountos, I.; Georgouli, T.; Henshaw, K.; Bird, H.; Jones, E.; Giannoudis, P.V. The effect of bone morphogenetic
protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the
proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone.
J. Orthop. Trauma 2010, 24, 552–556. [CrossRef] [PubMed]
12. Pountos, I.; Giannoudis, P.V.; Jones, E.; English, A.; Churchman, S.; Field, S.; Ponchel, F.; Bird, H.;
Emery, P.; McGonagle, D. NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis: Implications for
mechanism of bone formation inhibition in man. J. Cell. Mol. Med. 2011, 15, 525–534. [CrossRef] [PubMed]
13. Pountos, I.; Georgouli, T.; Giannoudis, P.V. The effect of autologous serum obtained after fracture on the
proliferation and osteogenic differentiation of mesenchymal stem cells. Cell. Mol. Biol. 2008, 54, 33–39.
[PubMed]
14. Pountos, I.; Corscadden, D.; Emery, P.; Giannoudis, P.V. Mesenchymal stem cell tissue engineering: Techniques
for isolation, expansion and application. Injury 2007, 38 (Suppl. 4), S23–S33. [CrossRef]
15. Horst, K.; Eschbach, D.; Pfeifer, R.; Hübenthal, S.; Sassen, M.; Steinfeldt, T.; Wulf, H.; Ruchholtz, S.; Pape, H.C.;
Hildebrand, F. Local inflammation in fracture hematoma: Results from a combined trauma model in pigs.
Mediat. Inflamm. 2015, 2015, 126060. [CrossRef]
16. Hauser, C.J.; Zhou, X.; Joshi, P.; Cuchens, M.A.; Kregor, P.; Devidas, M.; Kennedy, R.J.; Poole, G.V.; Hughes, J.L.
The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic
immunity. J. Trauma Acute Care Surg. 1997, 42, 895–904. [CrossRef]
17. Hauser, C.J.; Joshi, P.; Zhou, X.; Kregor, P.; Hardy, K.J.; Devidas, M.; Scott, P.; Hughes, J.L. Production of
interleukin-10 in human fracture soft-tissue hematomas. Shock 1996, 6, 3–6. [CrossRef]
18. Hoff, P.; Maschmeyer, P.; Gaber, T.; Schütze, T.; Raue, T.; Schmidt-Bleek, K.; Dziurla, R.; Schellmann, S.;
Lohanatha, F.L.; Röhner, E.; et al. Human immune cells’ behavior and survival under bioenergetically
restricted conditions in an in vitro fracture hematoma model. Cell. Mol. Immunol. 2013, 10, 151–158.
[CrossRef]
19. Boekholdt, S.M.; Peters, R.J.; Hack, C.E.; Day, N.E.; Luben, R.; Bingham, S.A.; Wareham, N.J.; Reitsma, P.H.;
Khaw, K.T. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthymen
and women: The EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol. 2004, 24,
1503–1508. [CrossRef]
J. Clin. Med. 2020, 9, 47 14 of 15
20. Ren, C.; Chen, Y.; Han, C.; Fu, D.; Chen, H. Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic
roles in patients with pancreatic cancer. Tumor Biol. 2014, 35, 11467–11472. [CrossRef]
21. Leon-Cabrera, S.; Arana-Lechuga, Y.; Esqueda-León, E.; Terán-Pérez, G.; Gonzalez-Chavez, A.; Escobedo, G.;
Velázquez Moctezuma, J. Reduced Systemic Levels of IL-10 Are Associated with the Severity of Obstructive
Sleep Apneaand Insulin Resistance in Morbidly Obese Humans. Mediat. Inflamm. 2015, 2015, 493409.
[CrossRef] [PubMed]
22. Traber, K.E.; Dimbo, E.L.; Symer, E.M.; Korkmaz, F.T.; Jones, M.R.; Mizgerd, J.P.; Quinton, L.J. Roles of
interleukin-11 during acute bacterial pneumonia. PLoS ONE 2019, 14, e0221029. [CrossRef] [PubMed]
23. Cavusoglu, E.; Marmur, J.D.; Hojjati, M.R.; Chopra, V.; Butala, M.; Subnani, R.; Huda, M.S.; Yanamadala, S.;
Ruwende, C.; Eng, C.; et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome.
Am. J. Med. 2011, 124, 724–730. [CrossRef] [PubMed]
24. Sobhan, M.R.; Farshchian, M.; Hoseinzadeh, A.; Ghasemibasir, H.R.; Solgi, G. Serum Levels of IL-10 and
IL-22 Cytokines in Patients with Psoriasis. Iran. J. Immunol. 2016, 13, 317–323.
25. Clemens, M. Cytokines, 1st ed.; Read, A.P., Brown, T., Eds.; Bios Scientific Publishers: Oxford, UK, 1991.
26. Hall, W.; Hall, E. Guidebook to Cytokines and Their Receptors; Nicola, N.A., Ed.; Oxford University Press:
Oxford, UK, 1994.
27. Glynne Andrew, J.; Andrew, S.M.; Freemont, A.J.; Marsh, D.R. Inflammatory cells in normal human fracture
healing. Acta Orthop. Scand. 1994, 65, 462–466. [CrossRef]
28. Giannoudis, P.V.; Einhorn, T.A.; Marsh, D. Fracture healing: The diamond concept. Injury 2007, 38, S3–S6.
[CrossRef]
29. McCarrel, T.; Fortier, L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized
platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J. Orthop. Res.
2009, 27, 1033–1042. [CrossRef]
30. Deuel, T.F.; Senior, R.M.; Huang, J.S.; Griffin, G.L. Chemotaxis of monocytes and neutrophils to
platelet-derived growth factor. J. Clin. Investig. 1982, 69, 1046–1049. [CrossRef]
31. Agrawal, S.; Ganguly, S.; Hajian, P.; Cao, J.N.; Agrawal, A. PDGF upregulates CLEC-2 to induce T regulatory
cells. Oncotarget 2015, 6, 28621–28632. [CrossRef]
32. Chen, C.F.; Feng, X.; Liao, H.Y.; Jin, W.J.; Zhang, J.; Wang, Y.; Gong, L.L.; Liu, J.J.; Yuan, X.H.; Zhao, B.B.; et al.
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci. Rep. 2014,
4, 6359. [CrossRef]
33. Tsunoda, M.; Mizuno, K.; Matsubara, T. The osteogenic potential of fracture hematoma and its mechanism on
bone formation–through fracture hematoma culture and transplantation of freeze-dried hematoma. Kobe J.
Med. Sci. 1993, 39, 35–50. [PubMed]
34. Hasegawa, T.; Miwa, M.; Sakai, Y.; Nikura, T.; Lee, S.Y.; Oe, K.; Iwakura, T.; Kurosaka, M.; Komori, T.
Mandibular Hematoma Cells as a Potential Reservoir for Osteoprogenitor Cells in Fractures. J. Oral
Maxillofac. Surg. 2012, 70, 599–607. [CrossRef] [PubMed]
35. Bendre, M.S.; Montague, D.C.; Peery, T.; Akel, N.S.; Gaddy, D.; Suva, L.J. Interleukin-8 stimulation of
osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
Bone 2016, 33, 28–37. [CrossRef]
36. Bordei, P. Locally applied platelet-derived growth factor accelerates fracture healing. J. Bone Jt. Surg. 2011,
93, 1653–1659. [CrossRef] [PubMed]
37. Mizuno, K.; Mineo, K.A.Z.U.O.; Tachibana, T.O.S.H.I.H.I.R.O.; Sumi, M.A.S.A.T.O.S.H.I.;
Matsubara, T.S.U.K.A.S.A.; Hirohata, K.A.Z.U.S.H.I. The osteogenetic potential of fracture haematoma.
Subperiosteal and intramuscular transplantation of the haematoma. J. Bone Jt. Surg. 1990, 72, 822–829.
[CrossRef]
38. Kuroyanagi, G.; Adapala, N.S.; Yamaguchi, R.; Kamiya, N.; Deng, Z.; Aruwajoye, O.; Kutschke, M.; Chen, E.;
Jo, C.; Ren, Y.; et al. Interleukin-6 deletion stimulates revascularization and new bone formation following
ischemic osteonecrosis in a murine model. Bone 2018, 116, 221–231. [CrossRef]
39. El-Zayadi, A.A.; Jones, E.A.; Churchman, S.M.; Baboolal, T.G.; Cuthbert, R.J.; El-Jawhari, J.J.; Badawy, A.M.;
Alase, A.A.; El-Sherbiny, Y.M.; McGonagle, D. Interleukin-22 drives the proliferation, migration and
osteogenic differentiation of mesenchymal stem cells: A novel cytokine that could contribute to new bone
formation in spondyloarthropathies. Rheumatology 2017, 56, 488–493. [CrossRef]
J. Clin. Med. 2020, 9, 47 15 of 15
40. Chen, E.; Liu, G.; Zhou, X.; Zhang, W.; Wang, C.; Hu, D.; Xue, D.; Pan, Z. Concentration-dependent, dual
roles of IL-10 in the osteogenesis of human BMSCs via P38/MAPK and NF-κB signaling pathways. FASEB J.
2018, 32, 4917–4929. [CrossRef]
41. BaoB, Y.Z.; LvC, X.L.; WangB, Y.Z.; WangA, G.F. IFN-γ induces senescence-like characteristics in mouse bone
marrow mesenchymal stem cells. Adv. Clin. Exp. Med. 2017, 26, 201–206.
42. Berendsen, A.D.; Olsen, B.R. How vascular endothelial growth factor-A (VEGF) regulates differentiation of
mesenchymal stem cells. J. Histochem. Cytochem. 2014, 62, 103–108. [CrossRef]
43. Hurley, M.M.; Adams, D.J.; Wang, L.; Jiang, X.; Burt, P.M.; Du, E.; Xiao, L. Accelerated fracture healing in
transgenic mice overexpressing an anabolic isoform of fibroblast growth factor 2. J. Cell. Biochem. 2016, 117,
599–611. [CrossRef] [PubMed]
44. Bell, D.M.; Leung, K.K.; Wheatley, S.C.; Ng, L.J.; Zhou, S.; Ling, K.W.; Sham, M.H.; Koopman, P.; Tam, P.P.;
Cheah, K.S. SOX9 directly regulates the type-II collagen gene. Nat. Genet. 1997, 16, 174–178. [CrossRef]
[PubMed]
45. Kokabu, S.; Gamer, L.; Cox, K.; Lowery, J.; Tsuji, K.; Raz, R.; Economides, A.; Katagiri, T.; Rosen, V.
BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.
Mol. Endocrinol. 2012, 26, 87–94. [CrossRef] [PubMed]
46. Checa, S.; Prendergast, P.J.; Duda, G.N. Inter-species investigation of the mechano-regulation of bone healing:
Comparison of secondarybone healing in sheep and rat. J. Biomech. 2011, 44, 1237–1245. [CrossRef] [PubMed]
47. Haffner-Luntzer, M.; Hankenson, K.D.; Ignatius, A.; Pfeifer, R.; Khader, B.A.; Hildebrand, F.;
van Griensven, M.; Pape, H.C.; Lehmicke, M. A Review of Animal Models of Comorbidities in
Fracture-Healing Research. J. Orthop. Resh. 2019, 37. [CrossRef] [PubMed]
48. Torricelli, P.; Fini, M.; Giavaresi, G.; Borsari, V.; Carpi, A.; Nicolini, A.; Giardino, R. Comparative interspecies
investigation on osteoblast cultures: Data on cell viability and syntheticactivity. Biomed. Pharmacother. 2003,
57, 57–62. [CrossRef]
49. Schell, H.; Duda, G.N.; Peters, A.; Tsitsilonis, S.; Johnson, K.A.; Schmidt-Bleek, K. The haematoma and its
role in bone healing. J. Exp. Orthop. 2017, 4, 5. [CrossRef]
50. Yang, X.; Yip, J.; Anastassiades, T.; Harrison, M.; Brockhausen, I. The action of TNFalpha and TGFbeta
include specific alterations of the glycosylation of bovine and human chondrocytes. Biochim. Biophys. Acta
2007, 1773, 264–272. [CrossRef]
51. Nemoto, K.; Pilbeam, C.C.; Bilak, S.R.; Raisz, L.G. Molecular cloning and expression of a rat prostaglandin
E2 receptor of the EP2 subtype. Prostaglandins 1997, 54, 713–725. [CrossRef]
52. Kasugai, S.; Oida, S.; Iimura, T.; Arai, N.; Takeda, K.; Ohya, K.; Sasaki, S. Expression of prostaglandin E
receptor subtypes in bone: Expression of EP2 in bone development. Bone 1995, 17, 1–4. [CrossRef]
53. Jiang, Y.; Lin, H.; Tuan, R.S. Overview: State of the Art and Future Prospectives for Cartilage Repair.
In Cartilage; Springer: Berlin/Heidelberg, Germany, 2017; Volume 3, pp. 1–34.
54. Malda, J.; de Grauw, J.C.; Benders, K.E.; Kik, M.J.; van de Lest, C.H.; Creemers, L.B.; Dhert, W.J.;
van Weeren, P.R. Of mice, men and elephants: The relation between articular cartilage thickness and
body mass. PLoS ONE 2013, 8, e57683. [CrossRef] [PubMed]
55. Wahl, E.C.; Aronson, J.; Liu, L.; Fowlkes, J.L.; Thrailkill, K.M.; Bunn, R.C.; Skinner, R.A.; Miller, M.J.;
Cockrell, G.E.; Clark, L.M.; et al. Restoration of regenerative osteoblastogenesis in aged mice: Modulation of
TNF. J. Bone Miner. Res. 2010, 25, 114–123. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
